Treatment with an N-cadherin-specific monoclonal antibody reduced proliferation, adhesion and invasion of prostate cancer cells in vitro, and slowed the growth of multiple established xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression [9]. Here, CDH2 is linked to prostate cancer.